Applications

 Jan 27, 2026

Elegen, today announced significant price reductions across its ENFINIA™ DNA portfolio, now offering high-accuracy, clonal, cell-free synthetic DNA with list pricing as low as $0.07 per base pair.  

SOURCE: Businesswire

Announcing the early access launch of Elegen’s Gen II DNA Production Platform. This platform now incorporates the world’s first directed split-pool microfluidic synthesizer, which augments Elegen’s unique cell-free cloning technology that ends the reliance on plasmids.

 Oct 28, 2025

SOURCE: Businesswire

 Sep 09, 2025

Elegen’s cell-free gene synthesis platform delivers full-length, high-complexity linear DNA with encoded poly(A) tails up to three times faster and free from bioburden, endotoxins and recombination-mediated variation.

SOURCE: Businesswire

INNOVATION IS OUR DNA

“The growing bioeconomy demands synthetic biology performs on a scale not possible without innovation of the DNA manufacturing process. Elegen will help the builders in the next evolution of synthetic biology eliminate expensive, time and capital-intensive workflows by using innovative methods and technologies to provide fast-turnaround, high-accuracy, complex, long, synthetic DNA.”

Matthew Hill
Founder and CEO of Elegen